Aerpio Pharmaceuticals, Inc.
ARPO · NASDAQ
12/31/2024 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.16 | 0.08 | 0.02 |
| FCF Yield | -102.92% | -45.98% | -46.92% | -118.69% |
| EV / EBITDA | -0.47 | -1.68 | -1.89 | -0.31 |
| Quality | ||||
| ROIC | -126.06% | -70.62% | -46.04% | -105.47% |
| Gross Margin | 0.00% | -535.75% | -347.36% | -1,655.04% |
| Cash Conversion Ratio | 0.93 | 0.88 | 1.02 | 0.82 |
| Growth | ||||
| Revenue 3-Year CAGR | 79.75% | 88.45% | – | – |
| Free Cash Flow Growth | 0.00% | -39.44% | -30.30% | -20.80% |
| Safety | ||||
| Net Debt / EBITDA | 0.41 | 0.41 | 0.45 | 0.47 |
| Interest Coverage | 438.04 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 82.92 | -17.49 | -20.75 | -24.16 |